https://novapharmanews.com/us/news/stat-corporate-medicine-telehealth-crackdown 2026-06-02T12:34:33.103Z NovaPharmaNews en 2026-06-02T12:28:43.909Z STAT+ Report: Corporate Medicine Crackdown Threatens Telehealth Business Models https://novapharmanews.com/uploads/articles/stat-corporate-medicine-telehealth-crackdown.webp STAT+ Report: Corporate Medicine Crackdown Threatens Telehealth Business Models https://novapharmanews.com/apac/news/global-rwe-guidance-regulatory-decision-making-updates 2026-06-02T10:42:33.586Z NovaPharmaNews en 2026-06-02T03:53:12.249Z Global Regulatory Agencies Update Real-World Evidence Guidance for Decision-Making https://novapharmanews.com/uploads/articles/global-rwe-guidance-regulatory-decision-making-updates.webp Global Regulatory Agencies Update Real-World Evidence Guidance for Decision-Making https://novapharmanews.com/apac/news/china-oncology-research-europe-alarm 2026-06-02T10:42:24.084Z NovaPharmaNews en 2026-06-02T03:48:14.665Z China's Ascendancy in Oncology Research Alarms European Oncologists, Threatening Europe's Competitive Edge oncology, cancer https://novapharmanews.com/uploads/articles/china-oncology-research-europe-alarm.webp China's Ascendancy in Oncology Research Alarms European Oncologists, Threatening Europe's Competitive Edge https://novapharmanews.com/apac/news/asco-2026-asian-oncology-innovation-clinical-trials 2026-06-02T07:13:24.485Z NovaPharmaNews en 2026-06-02T03:39:08.824Z ASCO 2026: Asian Oncology Innovation Takes Center Stage, Driving Global Clinical Trial Advancements oncology https://novapharmanews.com/uploads/articles/asco-2026-asian-oncology-innovation-clinical-trials.webp ASCO 2026: Asian Oncology Innovation Takes Center Stage, Driving Global Clinical Trial Advancements https://novapharmanews.com/us/news/inventiva-leadership-lanifibranor-phase-3-data 2026-06-02T07:01:25.302Z NovaPharmaNews en 2026-06-02T03:29:11.653Z Inventiva Bolsters Executive Team Ahead of Lanifibranor Phase 3 Data lanifibranor https://novapharmanews.com/uploads/articles/inventiva-leadership-lanifibranor-phase-3-data.webp Inventiva Bolsters Executive Team Ahead of Lanifibranor Phase 3 Data https://novapharmanews.com/eu/news/fda-approves-aldosterone-synthase-inhibitor-hypertension 2026-06-02T11:29:10.734Z NovaPharmaNews en 2026-06-02T03:29:11.653Z FDA Approves Baxdrostat (Baxfendy) as First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension baxdrostat, Baxfendy, hypertension https://novapharmanews.com/uploads/articles/fda-approves-aldosterone-synthase-inhibitor-hypertension.webp FDA Approves Baxdrostat (Baxfendy) as First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension https://novapharmanews.com/eu/news/x4-pharmaceuticals-mavorixafor-ema-approval 2026-06-02T10:18:06.961Z NovaPharmaNews en 2026-06-02T03:29:11.653Z X4 Pharmaceuticals' Mavorixafor Receives EMA Approval Recommendation for WHIM Syndrome Mavorixafor https://novapharmanews.com/uploads/articles/x4-pharmaceuticals-mavorixafor-ema-approval.webp X4 Pharmaceuticals' Mavorixafor Receives EMA Approval Recommendation for WHIM Syndrome https://novapharmanews.com/apac/news/newron-pharmaceuticals-june-investor-conferences 2026-06-02T10:17:15.016Z NovaPharmaNews en 2026-06-02T03:29:11.653Z Newron Pharmaceuticals to Present at Upcoming Investor Conferences https://novapharmanews.com/uploads/articles/newron-pharmaceuticals-june-investor-conferences.webp Newron Pharmaceuticals to Present at Upcoming Investor Conferences https://novapharmanews.com/apac/news/hong-kong-new-drug-approval-process 2026-06-02T03:29:11.653Z NovaPharmaNews en 2026-06-02T03:29:11.653Z Hong Kong Overhauls Drug Approval Process: What Pharma BD Teams Need to Know https://novapharmanews.com/uploads/articles/hong-kong-new-drug-approval-process.webp Hong Kong Overhauls Drug Approval Process: What Pharma BD Teams Need to Know https://novapharmanews.com/eu/news/datroway-priority-review-metastatic-tnbc 2026-06-02T07:13:27.062Z NovaPharmaNews en 2026-06-02T03:29:11.653Z Datroway Priority Review Fuels Hope for Metastatic Triple-Negative Breast Cancer Patients Datroway, breast cancer, metastatic triple-negative breast cancer https://novapharmanews.com/uploads/articles/datroway-priority-review-metastatic-tnbc.webp Datroway Priority Review Fuels Hope for Metastatic Triple-Negative Breast Cancer Patients https://novapharmanews.com/us/news/fda-expands-market-access-ends-products 2026-06-02T07:28:56.173Z NovaPharmaNews en 2026-06-02T03:29:11.653Z FDA Expands ENDS Market Access: Implications for Pharma BD and Investors https://novapharmanews.com/uploads/articles/fda-expands-market-access-ends-products.webp FDA Expands ENDS Market Access: Implications for Pharma BD and Investors https://novapharmanews.com/us/news/fda-draft-guidance-biosimilar-pk-studies 2026-06-02T10:19:41.985Z NovaPharmaNews en 2026-06-02T03:29:11.653Z FDA Draft Guidance Slashes Biosimilar PK Study Costs, Accelerating Market Entry https://novapharmanews.com/uploads/articles/fda-draft-guidance-biosimilar-pk-studies.webp FDA Draft Guidance Slashes Biosimilar PK Study Costs, Accelerating Market Entry https://novapharmanews.com/us/news/longeveron-stockholder-letter-corporate-strategy-2026-goals 2026-06-02T10:19:10.267Z NovaPharmaNews en 2026-06-02T03:29:11.653Z Longeveron Stockholder Letter Outlines 2026 Strategy and Partnership Focus https://novapharmanews.com/uploads/articles/longeveron-stockholder-letter-corporate-strategy-2026-goals.webp Longeveron Stockholder Letter Outlines 2026 Strategy and Partnership Focus https://novapharmanews.com/us/news/lilly-gilead-pharma-ma-boom-market-analysis 2026-06-02T03:29:11.653Z NovaPharmaNews en 2026-06-02T03:29:11.653Z Lilly and Gilead Drive Pharma M&A Surge: A Strategic Market Analysis cancer https://novapharmanews.com/uploads/articles/lilly-gilead-pharma-ma-boom-market-analysis.webp Lilly and Gilead Drive Pharma M&A Surge: A Strategic Market Analysis https://novapharmanews.com/us/news/new-fda-approach-drug-prices-implications 2026-06-02T11:50:24.721Z NovaPharmaNews en 2026-06-02T03:29:11.653Z FDA's New Stance on Drug Pricing: Impact on Approvals and Pharma Strategy https://novapharmanews.com/uploads/articles/new-fda-approach-drug-prices-implications.webp FDA's New Stance on Drug Pricing: Impact on Approvals and Pharma Strategy https://novapharmanews.com/us/news/fda-approves-atezolizumab-ctdna-mrd-positive-mibc 2026-06-02T03:29:11.653Z NovaPharmaNews en 2026-06-02T03:29:11.653Z FDA Approves Atezolizumab for ctDNA MRD-Positive MIBC: A New Era for Adjuvant Therapy atezolizumab, muscle invasive bladder cancer https://novapharmanews.com/uploads/articles/fda-approves-atezolizumab-ctdna-mrd-positive-mibc.webp FDA Approves Atezolizumab for ctDNA MRD-Positive MIBC: A New Era for Adjuvant Therapy https://novapharmanews.com/apac/news/beone-medicines-phase-3-herizon-gea-data-nejm 2026-06-02T03:29:11.653Z NovaPharmaNews en 2026-06-02T03:29:11.653Z BeOne Medicines' HERIZON-GEA Phase 3 Data in NEJM: A Deep Dive for Pharma BD and Investors https://novapharmanews.com/uploads/articles/beone-medicines-phase-3-herizon-gea-data-nejm.webp BeOne Medicines' HERIZON-GEA Phase 3 Data in NEJM: A Deep Dive for Pharma BD and Investors https://novapharmanews.com/eu/news/italy-fourth-europe-clinical-research-enrollment 2026-06-02T12:22:47.655Z NovaPharmaNews en 2026-06-02T03:29:11.653Z Italy's Clinical Research Landscape: Strengths, Weaknesses, and Strategic Implications https://novapharmanews.com/uploads/articles/italy-fourth-europe-clinical-research-enrollment.webp Italy's Clinical Research Landscape: Strengths, Weaknesses, and Strategic Implications https://novapharmanews.com/eu/news/mayer-brown-serb-pharmaceuticals-idefirix-acquisition 2026-06-02T07:20:53.656Z NovaPharmaNews en 2026-06-02T03:29:11.653Z SERB Pharmaceuticals Acquires European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma AB Idefirix, imlifidase https://novapharmanews.com/uploads/articles/mayer-brown-serb-pharmaceuticals-idefirix-acquisition.webp SERB Pharmaceuticals Acquires European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma AB https://novapharmanews.com/apac/news/dishman-carbogen-amcis-shanghai-nmpa-gmp-audit 2026-06-02T03:29:11.653Z NovaPharmaNews en 2026-06-02T03:29:11.653Z Dishman Carbogen Amcis Shanghai Site Achieves NMPA GMP Compliance with Zero Findings https://novapharmanews.com/uploads/articles/dishman-carbogen-amcis-shanghai-nmpa-gmp-audit.webp Dishman Carbogen Amcis Shanghai Site Achieves NMPA GMP Compliance with Zero Findings https://novapharmanews.com/eu/news/ema-implements-new-eu-pharma-rules-regulatory-updates 2026-06-02T10:18:59.654Z NovaPharmaNews en 2026-06-02T03:27:44.113Z EMA Initiates Implementation of New EU Pharmaceutical Legislation: What Pharma Needs to Know https://novapharmanews.com/uploads/articles/ema-implements-new-eu-pharma-rules-regulatory-updates.webp EMA Initiates Implementation of New EU Pharmaceutical Legislation: What Pharma Needs to Know https://novapharmanews.com/eu/news/regeneron-pharma-ema-eye-drug-review-wolfe-target-trim 2026-06-02T10:18:48.916Z NovaPharmaNews en 2026-06-02T03:20:47.528Z Regeneron Pharma Stock Holds Steady Amid EMA Eye Drug Review and Analyst Target Adjustment eye drug https://novapharmanews.com/uploads/articles/regeneron-pharma-ema-eye-drug-review-wolfe-target-trim.webp Regeneron Pharma Stock Holds Steady Amid EMA Eye Drug Review and Analyst Target Adjustment https://novapharmanews.com/eu/news/teva-olanzapine-lai-ema-review-schizophrenia 2026-06-02T05:06:50.066Z NovaPharmaNews en 2026-06-02T03:17:52.479Z Teva's Once-Monthly Schizophrenia Shot Enters EMA Review, Signaling New Treatment Option olanzapine, schizophrenia https://novapharmanews.com/uploads/articles/teva-olanzapine-lai-ema-review-schizophrenia.webp Teva's Once-Monthly Schizophrenia Shot Enters EMA Review, Signaling New Treatment Option https://novapharmanews.com/eu/news/asco-2026-european-pharma-astrazeneca-roche-market-analysis 2026-06-02T05:07:29.056Z NovaPharmaNews en 2026-06-02T03:10:06.470Z ASCO 2026: European Pharma's Quiet Showing and What AstraZeneca & Roche Must Address https://novapharmanews.com/uploads/articles/asco-2026-european-pharma-astrazeneca-roche-market-analysis.webp ASCO 2026: European Pharma's Quiet Showing and What AstraZeneca & Roche Must Address https://novapharmanews.com/eu/news/esmo-2025-nmi-bladder-cancer-highlights 2026-06-02T05:05:45.070Z NovaPharmaNews en 2026-06-02T03:05:38.541Z ESMO 2025: Key Advances in Non-Muscle-Invasive Bladder Cancer Shape Future Oncology Strategies oncology, non-muscle-invasive bladder cancer https://novapharmanews.com/uploads/articles/esmo-2025-nmi-bladder-cancer-highlights.webp ESMO 2025: Key Advances in Non-Muscle-Invasive Bladder Cancer Shape Future Oncology Strategies https://novapharmanews.com/eu/news/datroway-trodelvy-first-line-tnbc-battle 2026-06-02T05:05:37.325Z NovaPharmaNews en 2026-06-02T03:00:26.076Z Datroway and Trodelvy Vie for First-Line TNBC Dominance Amidst Evolving Treatment Landscape Datroway, Trodelvy, oncology, breast cancer https://novapharmanews.com/uploads/articles/datroway-trodelvy-first-line-tnbc-battle.webp Datroway and Trodelvy Vie for First-Line TNBC Dominance Amidst Evolving Treatment Landscape https://novapharmanews.com/us/news/citius-pharmaceuticals-stock-update-cancer-anti-infective 2026-06-02T02:57:43.592Z NovaPharmaNews en 2026-06-02T02:57:43.611Z Citius Pharmaceuticals Stock Update: Cancer and Anti-Infective Pipeline Insights cancer, anti-infective https://novapharmanews.com/uploads/articles/citius-pharmaceuticals-stock-update-cancer-anti-infective.webp Citius Pharmaceuticals Stock Update: Cancer and Anti-Infective Pipeline Insights https://novapharmanews.com/eu/news/idorsia-c-diff-vaccine-clinical-progress 2026-06-02T05:05:37.653Z NovaPharmaNews en 2026-06-02T02:47:49.435Z Idorsia's C. difficile Vaccine Shows Continued Positive Clinical Progress IDOR-1134-2831, Clostridioides difficile infection https://novapharmanews.com/uploads/articles/idorsia-c-diff-vaccine-clinical-progress.webp Idorsia's C. difficile Vaccine Shows Continued Positive Clinical Progress https://novapharmanews.com/us/news/fda-guidance-animal-thyroid-products-august-2026 2026-06-02T04:14:46.297Z NovaPharmaNews en 2026-06-02T02:35:54.944Z FDA to Issue Guidance on Animal-Derived Thyroid Products by August 2026, Signaling Regulatory Shift NP Thyroid, Desiccated Thyroid Extract, Graves' Disease https://novapharmanews.com/uploads/articles/fda-guidance-animal-thyroid-products-august-2026.webp FDA to Issue Guidance on Animal-Derived Thyroid Products by August 2026, Signaling Regulatory Shift https://novapharmanews.com/us/news/global-regulatory-roundup-june-1-2026 2026-06-02T03:21:29.267Z NovaPharmaNews en 2026-06-02T02:31:43.284Z Global Regulatory Roundup: Key Updates for June 1, 2026 Dermatologicals, oncology, Neurological, Rare Diseases https://novapharmanews.com/uploads/articles/global-regulatory-roundup-june-1-2026.webp Global Regulatory Roundup: Key Updates for June 1, 2026 https://novapharmanews.com/us/news/biotech-m-and-a-trends-2026-outlook 2026-06-02T03:22:32.401Z NovaPharmaNews en 2026-06-02T02:27:52.983Z Biotech M&A Trends: Navigating the 2026 Outlook for Strategic Growth https://novapharmanews.com/uploads/articles/biotech-m-and-a-trends-2026-outlook.webp Biotech M&A Trends: Navigating the 2026 Outlook for Strategic Growth https://novapharmanews.com/us/news/big-pharma-small-deals-biotech-boon 2026-06-02T03:19:52.006Z NovaPharmaNews en 2026-06-02T02:21:10.753Z Big Pharma's Shift to Smaller Deals Boosts Biotech Sector https://novapharmanews.com/uploads/articles/big-pharma-small-deals-biotech-boon.webp Big Pharma's Shift to Smaller Deals Boosts Biotech Sector https://novapharmanews.com/us/news/rallybio-avenzo-reverse-merger-oncology-deal 2026-06-02T03:22:54.048Z NovaPharmaNews en 2026-06-02T02:18:08.248Z Rallybio Taps Avenzo Therapeutics for Reverse Merger to Advance Oncology Pipeline https://novapharmanews.com/uploads/articles/rallybio-avenzo-reverse-merger-oncology-deal.webp Rallybio Taps Avenzo Therapeutics for Reverse Merger to Advance Oncology Pipeline https://novapharmanews.com/us/news/legend-biotech-asco-data-carvykti-lb2102 2026-06-02T06:26:58.001Z NovaPharmaNews en 2026-06-02T02:06:25.818Z Legend Biotech Presents Promising CARVYKTI and LB2102 Data at ASCO LB2102, CARVYKTI https://novapharmanews.com/uploads/articles/legend-biotech-asco-data-carvykti-lb2102.webp Legend Biotech Presents Promising CARVYKTI and LB2102 Data at ASCO https://novapharmanews.com/us/news/cdc-ebola-containment-clinical-trials-priority 2026-06-02T07:29:24.655Z NovaPharmaNews en 2026-06-02T02:01:43.120Z CDC Prioritizes Ebola Containment, Highlighting Critical Role of Clinical Trials Ebola https://novapharmanews.com/uploads/articles/cdc-ebola-containment-clinical-trials-priority.webp CDC Prioritizes Ebola Containment, Highlighting Critical Role of Clinical Trials https://novapharmanews.com/us/news/asia-biopharma-innovation-epicenter-drug-approvals 2026-06-02T06:26:57.972Z NovaPharmaNews en 2026-06-02T01:50:57.481Z Asia Surges as Biopharma Innovation Hub, Driving Global Drug Approvals https://novapharmanews.com/uploads/articles/asia-biopharma-innovation-epicenter-drug-approvals.webp Asia Surges as Biopharma Innovation Hub, Driving Global Drug Approvals https://novapharmanews.com/us/news/dea-reschedules-marijuana-schedule-iii-expediting-medical-access-research 2026-06-02T03:23:18.563Z NovaPharmaNews en 2026-06-02T01:47:13.789Z DEA Reschedules Marijuana to Schedule III, Expediting Medical Access and Research https://novapharmanews.com/uploads/articles/dea-reschedules-marijuana-schedule-iii-expediting-medical-access-research.webp DEA Reschedules Marijuana to Schedule III, Expediting Medical Access and Research https://novapharmanews.com/us/news/fda-expert-panel-review-peptide-access-compounded-drug-market 2026-06-02T04:56:20.821Z NovaPharmaNews en 2026-06-02T01:42:09.232Z FDA Expert Panel to Review Peptide Access, Impacting Compounded Drug Market https://novapharmanews.com/uploads/articles/fda-expert-panel-review-peptide-access-compounded-drug-market.webp FDA Expert Panel to Review Peptide Access, Impacting Compounded Drug Market https://novapharmanews.com/us/news/elite-pharma-fda-anda-generic-anticoagulant-26b 2026-06-02T04:50:00.562Z NovaPharmaNews en 2026-06-02T01:32:47.226Z Elite Pharma Files FDA ANDA for $26B Generic Blood Thinner, Targeting Key Anticoagulant Market blood thinner https://novapharmanews.com/uploads/articles/elite-pharma-fda-anda-generic-anticoagulant-26b.webp Elite Pharma Files FDA ANDA for $26B Generic Blood Thinner, Targeting Key Anticoagulant Market https://novapharmanews.com/us/news/cms-finalizes-medicaid-work-requirement-rules 2026-06-02T06:29:57.491Z NovaPharmaNews en 2026-06-02T01:22:36.164Z CMS Finalizes Medicaid Work Requirement Rules, Impacting State Programs and Pharma Strategy https://novapharmanews.com/uploads/articles/cms-finalizes-medicaid-work-requirement-rules.webp CMS Finalizes Medicaid Work Requirement Rules, Impacting State Programs and Pharma Strategy https://novapharmanews.com/us/news/medicus-pharma-biotech-showcase-2026 2026-06-02T11:28:13.260Z NovaPharmaNews en 2026-06-01T23:38:28.408Z Medicus Pharma Ltd. to Present at Biotech Showcase 2026, Advancing SkinJect Program https://novapharmanews.com/uploads/articles/medicus-pharma-biotech-showcase-2026.webp Medicus Pharma Ltd. to Present at Biotech Showcase 2026, Advancing SkinJect Program https://novapharmanews.com/us/news/rigel-pharmaceuticals-licenses-veppanu 2026-06-01T22:41:06.178Z NovaPharmaNews en 2026-06-01T22:23:48.621Z Rigel Pharmaceuticals Licenses FDA-Approved Breast Cancer Drug VEPPANU VEPPANU, breast cancer https://novapharmanews.com/uploads/articles/rigel-pharmaceuticals-licenses-veppanu.webp Rigel Pharmaceuticals Licenses FDA-Approved Breast Cancer Drug VEPPANU https://novapharmanews.com/us/news/fda-ai-clinical-trials-rfi-guide 2026-06-02T08:53:41.357Z NovaPharmaNews en 2026-06-01T21:30:56.231Z Accelerating Drug Development: FDA's AI Clinical Trials RFI Guide https://novapharmanews.com/uploads/articles/fda-ai-clinical-trials-rfi-guide.webp Accelerating Drug Development: FDA's AI Clinical Trials RFI Guide https://novapharmanews.com/apac/news/estado-actual-y-acciones-para-impulsar-la-investigacion-clinica-en-mexico-2025-5b7db092 2026-06-01T21:10:53.742Z NovaPharmaNews en 2026-06-01T21:10:53.755Z Estado Actual y Acciones para Impulsar la Investigación Clínica en México: 2025 https://novapharmanews.com/uploads/articles/estado-actual-y-acciones-para-impulsar-la-investigacion-clinica-en-mexico-2025-5b7db092.webp Estado Actual y Acciones para Impulsar la Investigación Clínica en México: 2025 https://novapharmanews.com/us/news/formycon-ag-geschaftsbericht-2025-5ff7fa30 2026-06-01T21:24:40.307Z NovaPharmaNews en 2026-06-01T21:04:54.385Z Formycon AG Geschäftsbericht 2025: Key Insights and Implications https://novapharmanews.com/uploads/articles/formycon-ag-geschaftsbericht-2025-5ff7fa30.webp Formycon AG Geschäftsbericht 2025: Key Insights and Implications https://novapharmanews.com/us/news/top-biotech-gainers-codx-nrxp-nvax-clinical-trials-update 2026-06-02T07:19:10.527Z NovaPharmaNews en 2026-06-01T06:15:59.933Z Top Biotech Gainers: CODX, NRXP, NVAX - Clinical Trials Update CODX, NRXP, NVAX, Ebola https://novapharmanews.com/uploads/articles/top-biotech-gainers-codx-nrxp-nvax-clinical-trials-update.webp Top Biotech Gainers: CODX, NRXP, NVAX - Clinical Trials Update https://novapharmanews.com/us/news/fda-flashback-breast-cancer-april-2026 2026-06-02T02:52:40.411Z NovaPharmaNews en 2026-06-01T06:15:59.933Z FDA Flashback: Key Breast Cancer Decisions from April 2026 oncology, breast cancer https://novapharmanews.com/uploads/articles/fda-flashback-breast-cancer-april-2026.webp FDA Flashback: Key Breast Cancer Decisions from April 2026 https://novapharmanews.com/us/news/fda-peptides-bulk-drug-compounding 2026-06-02T12:12:20.959Z NovaPharmaNews en 2026-06-01T06:15:59.933Z FDA Considers Adding Peptides to Bulk Drug Compounding List https://novapharmanews.com/uploads/articles/fda-peptides-bulk-drug-compounding.webp FDA Considers Adding Peptides to Bulk Drug Compounding List https://novapharmanews.com/us/news/ophthalmology-pipeline-milestones-q2-2026 2026-06-02T06:04:02.489Z NovaPharmaNews en 2026-06-01T06:15:59.933Z Ophthalmology Pipeline Milestones for Q2 2026: What to Expect https://novapharmanews.com/uploads/articles/ophthalmology-pipeline-milestones-q2-2026.webp Ophthalmology Pipeline Milestones for Q2 2026: What to Expect https://novapharmanews.com/us/news/fda-approvals-oncology-jan-mar-2026 2026-06-02T08:55:19.348Z NovaPharmaNews en 2026-06-01T06:15:59.933Z FDA Approvals in Oncology: January-March 2026 oncology https://novapharmanews.com/uploads/articles/fda-approvals-oncology-jan-mar-2026.webp FDA Approvals in Oncology: January-March 2026 https://novapharmanews.com/us/news/sunlight-glp-1-2026-fda-decision-compounded-semaglutide 2026-06-02T11:33:42.487Z NovaPharmaNews en 2026-06-01T06:15:59.933Z Sunlight GLP-1 2026: FDA's Decision on Compounded Semaglutide semaglutide, GLP-1 https://novapharmanews.com/uploads/articles/sunlight-glp-1-2026-fda-decision-compounded-semaglutide.webp Sunlight GLP-1 2026: FDA's Decision on Compounded Semaglutide https://novapharmanews.com/us/news/fda-permanent-ban-compounded-glp-1s 2026-06-02T06:44:01.097Z NovaPharmaNews en 2026-06-01T06:15:59.933Z FDA's Permanent Ban on Compounded GLP-1s: What It Means for Pharma GLP-1 https://novapharmanews.com/uploads/articles/fda-permanent-ban-compounded-glp-1s.webp FDA's Permanent Ban on Compounded GLP-1s: What It Means for Pharma https://novapharmanews.com/us/news/2025-drug-approvals-biopharma-resilience 2026-06-02T06:58:28.917Z NovaPharmaNews en 2026-06-01T06:15:59.933Z 2025 Drug Approvals: Biopharma's Resilience Amidst Challenges https://novapharmanews.com/uploads/articles/2025-drug-approvals-biopharma-resilience.webp 2025 Drug Approvals: Biopharma's Resilience Amidst Challenges https://novapharmanews.com/us/news/fda-easing-restrictions-unproven-peptides 2026-06-02T10:06:22.699Z NovaPharmaNews en 2026-06-01T06:15:59.933Z FDA Considers Easing Restrictions on Unproven Peptides https://novapharmanews.com/uploads/articles/fda-easing-restrictions-unproven-peptides.webp FDA Considers Easing Restrictions on Unproven Peptides https://novapharmanews.com/us/news/fda-eases-restrictions-peptides-drug-approvals 2026-06-02T10:13:59.325Z NovaPharmaNews en 2026-06-01T06:15:59.933Z FDA Eases Restrictions on Peptides: Implications for Drug Approvals https://novapharmanews.com/uploads/articles/fda-eases-restrictions-peptides-drug-approvals.webp FDA Eases Restrictions on Peptides: Implications for Drug Approvals https://novapharmanews.com/us/news/eli-lilly-acquires-centessa-pharmaceuticals-market-analysis 2026-06-02T05:50:00.912Z NovaPharmaNews en 2026-06-01T06:15:59.933Z Eli Lilly Acquires Centessa Pharmaceuticals: Market Analysis https://novapharmanews.com/uploads/articles/eli-lilly-acquires-centessa-pharmaceuticals-market-analysis.webp Eli Lilly Acquires Centessa Pharmaceuticals: Market Analysis https://novapharmanews.com/us/news/bayer-acquisition-eye-drug-biotech 2026-06-02T04:52:23.277Z NovaPharmaNews en 2026-06-01T06:15:59.933Z Bayer's $300M Acquisition: A Strategic Move in Ophthalmology https://novapharmanews.com/uploads/articles/bayer-acquisition-eye-drug-biotech.webp Bayer's $300M Acquisition: A Strategic Move in Ophthalmology https://novapharmanews.com/us/news/top-10-takeover-targets-2026 2026-06-02T11:35:37.757Z NovaPharmaNews en 2026-06-01T06:15:59.933Z Top 10 Takeover Targets of 2026: Market Analysis https://novapharmanews.com/uploads/articles/top-10-takeover-targets-2026.webp Top 10 Takeover Targets of 2026: Market Analysis https://novapharmanews.com/us/news/us-fda-proposes-regulations-weight-loss-drug-compounding 2026-06-02T12:11:29.547Z NovaPharmaNews en 2026-06-01T06:15:59.933Z US FDA Proposes New Regulations on Weight-Loss Drug Compounding semaglutide, liraglutide, weight loss https://novapharmanews.com/uploads/articles/us-fda-proposes-regulations-weight-loss-drug-compounding.webp US FDA Proposes New Regulations on Weight-Loss Drug Compounding https://novapharmanews.com/eu/news/ascentage-pharma-eha-2026-clinical-advances 2026-06-02T05:24:35.386Z NovaPharmaNews en 2026-06-01T06:15:53.438Z Ascentage Pharma's 17 Clinical Advances at EHA 2026 https://novapharmanews.com/uploads/articles/ascentage-pharma-eha-2026-clinical-advances.webp Ascentage Pharma's 17 Clinical Advances at EHA 2026 https://novapharmanews.com/eu/news/rethinking-qa-qc-future-bio-pharmaceutical-analysis-2026 2026-06-02T03:52:07.974Z NovaPharmaNews en 2026-06-01T06:15:53.438Z Rethinking QA/QC at The Future of Bio/Pharmaceutical Analysis 2026 https://novapharmanews.com/uploads/articles/rethinking-qa-qc-future-bio-pharmaceutical-analysis-2026.webp Rethinking QA/QC at The Future of Bio/Pharmaceutical Analysis 2026 https://novapharmanews.com/eu/news/us-europe-biosimilar-approvals-2026 2026-06-01T19:48:46.749Z NovaPharmaNews en 2026-06-01T06:15:53.438Z Biosimilar Approvals: U.S. vs. Europe Insights https://novapharmanews.com/uploads/articles/us-europe-biosimilar-approvals-2026.webp Biosimilar Approvals: U.S. vs. Europe Insights https://novapharmanews.com/eu/news/fda-delays-astrazeneca-breast-cancer-drug-review 2026-06-02T04:53:38.558Z NovaPharmaNews en 2026-06-01T06:15:53.438Z FDA Delays AstraZeneca's Breast Cancer Drug Review: Key Insights breast cancer https://novapharmanews.com/uploads/articles/fda-delays-astrazeneca-breast-cancer-drug-review.webp FDA Delays AstraZeneca's Breast Cancer Drug Review: Key Insights https://novapharmanews.com/eu/news/international-school-clinical-oncology-annual-congress-2026 2026-06-02T12:25:23.189Z NovaPharmaNews en 2026-06-01T06:15:53.438Z International School of Clinical Oncology Annual Congress 2026: Key Insights oncology https://novapharmanews.com/uploads/articles/international-school-clinical-oncology-annual-congress-2026.webp International School of Clinical Oncology Annual Congress 2026: Key Insights https://novapharmanews.com/eu/news/2026-italy-drug-medical-device-litigation-report 2026-06-02T04:55:07.618Z NovaPharmaNews en 2026-06-01T06:15:53.438Z 2026 Italy Drug & Medical Device Litigation Report: Key Insights https://novapharmanews.com/uploads/articles/2026-italy-drug-medical-device-litigation-report.webp 2026 Italy Drug & Medical Device Litigation Report: Key Insights https://novapharmanews.com/eu/news/bio-pharma-outlook-2026-regulatory-updates 2026-06-02T08:57:48.085Z NovaPharmaNews en 2026-06-01T06:15:53.438Z Bio/Pharma Outlook 2026: Regulatory Updates and Implications https://novapharmanews.com/uploads/articles/bio-pharma-outlook-2026-regulatory-updates.webp Bio/Pharma Outlook 2026: Regulatory Updates and Implications https://novapharmanews.com/eu/news/who-europe-access-novel-medicines 2026-06-01T23:35:29.547Z NovaPharmaNews en 2026-06-01T06:15:53.438Z WHO/Europe's Initiative on Access to Novel Medicines https://novapharmanews.com/uploads/articles/who-europe-access-novel-medicines.webp WHO/Europe's Initiative on Access to Novel Medicines https://novapharmanews.com/eu/news/horizon-scanning-ema-regulatory-updates 2026-06-02T05:45:51.988Z NovaPharmaNews en 2026-06-01T06:15:53.438Z Horizon Scanning at EMA: Regulatory Updates for Future Medicines https://novapharmanews.com/uploads/articles/horizon-scanning-ema-regulatory-updates.webp Horizon Scanning at EMA: Regulatory Updates for Future Medicines https://novapharmanews.com/us/news/fda-guidance-next-gen-sequencing-gene-therapy-safety 2026-06-02T11:50:22.039Z NovaPharmaNews en 2026-06-01T06:15:53.438Z FDA Guidance on Next-Gen Sequencing for Gene Therapy Safety gene therapy https://novapharmanews.com/uploads/articles/fda-guidance-next-gen-sequencing-gene-therapy-safety.webp FDA Guidance on Next-Gen Sequencing for Gene Therapy Safety https://novapharmanews.com/us/news/pharma-in-focus-regulatory-updates 2026-06-02T11:25:59.611Z NovaPharmaNews en 2026-06-01T06:15:53.438Z Pharma in Focus: Regulatory Updates You Need to Know https://novapharmanews.com/uploads/articles/pharma-in-focus-regulatory-updates.webp Pharma in Focus: Regulatory Updates You Need to Know https://novapharmanews.com/us/news/healthcare-dealmaker-megamergers-2026 2026-06-02T08:57:42.617Z NovaPharmaNews en 2026-06-01T06:15:53.438Z Healthcare Dealmakers Target Megamergers in 2026 https://novapharmanews.com/uploads/articles/healthcare-dealmaker-megamergers-2026.webp Healthcare Dealmakers Target Megamergers in 2026 https://novapharmanews.com/us/news/fsma-final-rule-traceability-requirements 2026-06-02T08:58:05.055Z NovaPharmaNews en 2026-06-01T06:15:53.438Z FSMA Final Rule: New Traceability Requirements Impacting Food Safety https://novapharmanews.com/uploads/articles/fsma-final-rule-traceability-requirements.webp FSMA Final Rule: New Traceability Requirements Impacting Food Safety https://novapharmanews.com/apac/news/decade-ai-medical-device-regulation-2015-2025 2026-06-02T01:01:14.859Z NovaPharmaNews en 2026-06-01T06:15:53.438Z A Decade of AI Medical Device Regulation: Key Updates https://novapharmanews.com/uploads/articles/decade-ai-medical-device-regulation-2015-2025.webp A Decade of AI Medical Device Regulation: Key Updates https://novapharmanews.com/apac/news/early-access-disparities-innovative-therapies 2026-06-01T23:58:53.599Z NovaPharmaNews en 2026-06-01T06:15:53.438Z Disparities in Early Access to Innovative Therapies: A Global Overview https://novapharmanews.com/uploads/articles/early-access-disparities-innovative-therapies.webp Disparities in Early Access to Innovative Therapies: A Global Overview https://novapharmanews.com/apac/news/pharmaceuticals-market-size-share-analysis-2034 2026-06-01T23:59:09.618Z NovaPharmaNews en 2026-06-01T06:15:53.438Z Pharmaceuticals Market Size and Share Analysis for 2034 https://novapharmanews.com/uploads/articles/pharmaceuticals-market-size-share-analysis-2034.webp Pharmaceuticals Market Size and Share Analysis for 2034 https://novapharmanews.com/apac/news/akeso-lung-cancer-drug-outperforms-immunotherapy 2026-06-02T01:02:48.047Z NovaPharmaNews en 2026-06-01T06:15:53.438Z Akeso Lung Cancer Drug Outperforms Immunotherapy in China Trial oncology, lung cancer https://novapharmanews.com/uploads/articles/akeso-lung-cancer-drug-outperforms-immunotherapy.webp Akeso Lung Cancer Drug Outperforms Immunotherapy in China Trial